Sigyn Therapeutics is advancing CardioDialysis, a medical device designed to treat cardiovascular disease through blood purification, with potential to significantly reduce Major Adverse Cardiovascular Events. The technology leverages existing dialysis infrastructure, positioning it for broader adoption than current FDA-approved lipoprotein apheresis treatments that are limited to approximately 60 specialized centers in the United States.
Current cardiovascular disease therapies face significant limitations. While LDL-C reducing statins are associated with 25% reductions in MACE according to a source publication, the American Heart Association reports that blood purification through lipoprotein apheresis shows 75% to 95% reductions in MACE as detailed in another publication. CardioDialysis aims to build upon these results while overcoming infrastructure barriers that limit current blood purification treatments.
The device's deployment on existing dialysis machines at more than 7,500 U.S. kidney dialysis clinics represents a significant advantage over lipoprotein apheresis devices that cannot operate on dialysis equipment. This infrastructure advantage could enable broader patient access to blood purification therapy for cardiovascular disease.
CardioDialysis demonstrates broad-spectrum clearance capabilities, addressing twelve therapeutic targets below 200nm in diameter from human blood plasma, including inflammatory molecules not targeted by current market-approved therapies. The technology has shown safety and tolerability in porcine animal studies conducted at the University of Michigan.
An immediate clinical opportunity exists in treating cardiovascular disease in end-stage renal disease patients, who represent a population with particularly high cardiovascular risk. The U.S. Renal Data System reports cardiovascular disease accounts for 67% of ESRD patient deaths, with incidence up to 20 times higher than in the general population. Current drugs have not reduced cardiovascular events in dialysis patients, and lipoprotein(a) levels are 2-4 times higher in this population.
The clinical strategy for CardioDialysis enrollment of ESRD patients at their dialysis clinics during regularly scheduled treatments offers efficiency advantages over traditional ICU-based studies for life-threatening conditions. This approach could significantly reduce the time and cost required for human feasibility and pivotal efficacy studies needed for FDA market approval consideration.
For the dialysis industry, successful implementation of CardioDialysis could have substantial financial implications. With cardiovascular disease as the leading cause of ESRD deaths, reducing MACE would extend patient lives, potentially increasing top-line dialysis industry revenues by $2.8 billion for each month of extended patient life based on average annual per-patient revenues of $65,000. The technology also creates a potential pathway for dialysis clinics to expand into cardiovascular disease treatment for the general population, potentially transforming current kidney dialysis centers into future renal and CardioDialysis treatment facilities.
The development represents a convergence of dialysis technology and cardiovascular treatment that could address significant unmet medical needs while creating new commercial opportunities within existing healthcare infrastructure.
